ELTX - Elicio Therapeutics, Inc.

5.315
-0.695   -13.076%

Share volume: 27,024
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$6.01
-0.69
-0.12%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 0%
Dept financing 50%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.36%
1 Month
-30.61%
3 Months
-6.26%
6 Months
15.03%
1 Year
-38.63%
2 Year
0.66%
Key data
Stock price
$5.32
P/E Ratio 
0.00
DAY RANGE
$5.21 - $5.81
EPS 
-$3.18
52 WEEK RANGE
$3.34 - $11.45
52 WEEK CHANGE
-$39.60
MARKET CAP 
54.196 M
YIELD 
N/A
SHARES OUTSTANDING 
10.775 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$77,103
AVERAGE 30 VOLUME 
$49,904
Company detail
CEO: Robert T. Connelly
Region: US
Website: elicio.com
Employees: 23
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.

Recent news
loading